Traws Pharma, Inc. ( NASDAQ: TRAW) Virtual Investor Event March 31, 2025 10:00 AM ET Werner Cautreels – Chief Executive Officer Robert Redfield – Chief Medical Officer David Pauza – Chief Science ...

Vaxcyte’s stock has dropped around 45% despite a Phase II trial of its invasive pneumococcal disease (IPD) vaccine meeting ...

Patients with active cancer who developed a blood clot, or venous thromboembolism (VTE), and were treated with blood-thinning ...

Tivoxavir marboxil’s potential as a single dose therapeutic agent for bird flu supported by significant antiviral activity in three well accepted ...

Vaxcyte's VAX-24 Phase 2 trial showed a safety profile similar to PCV20, with strong immune responses and no serious ...

Preparations are underway for a limited spring COVID-19 vaccination program in Alberta.Pharmacists say certain groups of high ...

Just as effective as the high dose, low-dose apixaban prevents long-term recurrent venous thromboembolism in patients with ...

Patients with active cancer who developed a blood clot, or venous thromboembolism (VTE), and were treated with blood-thinning medication for at least six months, followed by an additional 12 months of ...

For extended anticoagulation after venous thromboembolism (VTE) in patients with active cancer, a lower dose of apixaban ...

In his resignation letter, Marks wrote that health secretary Robert F. Kennedy Jr. wanted "subservient confirmation of his ...

Claim construction hearing for Pfizer/BioNTech mRNA-LNP vaccine litigation occurred in December 2024; outcome pending Jury trial in Moderna U.S.